by NeOnc Technologies | Jul 6, 2021
Main > NEO212 NEO212 Research | JULY 6, 2021 > NEO-212 Shows Promise In Treating Acute Myeloid Leukemia Acute Myeloid Leukemia (AML) is a difficult to treat cancer that starts in the bone marrow and then moves quickly into the blood allowing it to spread to...
by NeOnc Technologies | Nov 20, 2020
Main > NEO212 NEO100 Research | NOVEMBER 20, 2020 > Understanding The Pharmacokinetic Properties Of NEO 212 This study was conducted to characterize the metabolism and pharmacokinetic properties of NEO 212 in preclinical models. NEO 212, a conjugate of...
by NeOnc Technologies | May 10, 2020
Main > NEO212 NEO212 Research | MAY 10, 2020 NEO 212 Enhances Temozolomide’s Ability To Increase Radiosensitivity And Cytotoxicity In Glioblastoma Tumors A new study into the effectiveness of NEO212, a conjugate formulation of Temozolomide (TMZ) and Perillyl...
by NeOnc Technologies | Nov 27, 2018
Main > NEO212 NEO212 Research | November 27, 2015 > TMZ-POH Shows Positive Effect On Patients With Nasopharyngeal Carcinoma. In this study, Neonc Technologies Holdings, Inc. showed that the cytotoxicity effects of its patented NEO212 compound Nasopharyngeal...
by NeOnc Technologies | Oct 24, 2018
Main > NEO212 NEO212 Research | Oct. 24, 2018 NEO212 Shows Ability To Help Block Pro-Angiogenic And Invasive Characteristics Of GBM NeOnc Technologies Holdings conducted a study to examine the effects of its NEO212 formulation in helping to block one of the key...
